Dr. Weeks’ Comment: Here is the most recent addition to the increasingly persuasive argument that any oncologist who does NOT target your cancer STEM cells is not only negligent and uninformed, he or she is dangerous – to be precise: LETHAL. The Standard of Care – the irresponsible opinion that consensus among experts determines correctness (remember: science is not a business of consensus, it is a rigorous experimental discipline) – insists that oncologists use the terrible trio: PCB = Poison (chemo), Cut (surgery) and Burn (radiation). This is required EVEN though it is NOT helpful (remember: the data reveals people who survive PCB typically survive DESPITE the standard of care treatment). So, if you or someone you love has cancer, study up on cancer STEM cells.
Read the new article below and then study these key articles
THIS THIS THIS THIS THIS AND THIS
and watch these lectures Dr. Weeks has given on the topic of cancer STEM cells.
HERE HERE HERE HERE HERE HERE HERE HERE
(also search “cancer stem cell” in the search engine at www.weeksmd.com)
“The recognition that cancers may rely on “cancer stem cells” that share the self-renewal feature of normal stem cells has changed the perspective with regard to new approaches for treating the disease.”
“These cancer stem cells are rare (about 1 in 250,000 tumor cells), but are the only cells with the capability to produce a new tumor.”
‘Both approaches have resulted in limited successes for certain cases, but neither approach completely cures cancer, targeting downstream cancerous cells, rather than the source.”
“Clearly, the solution to effective therapies is to target the rare cells from whence the cancer originates, rather than all the cells of the tumor, in an effort to eliminate the disease itself and prevent these cancer stem cells from repopulating the tumor once the bulk is killed off.”
Cancer Stem Cell Research: The Future Direction
1Department of Biological Sciences, Ohio University Zanesville, USA 2Fisher College of Business, The Ohio State University, USA
Received: April 15, 2014 | Published: April 23, 2014
Citation: Saghir MAL, Ajlouni B (2014) Cancer Stem Cell Research: The Future Direction. MOJ Cell Sci Report 1(1): 00002.
Scientists have tried for many years to understand cancer development in the context of therapeutic strategies.
The recognition that cancers may rely on “cancer stem cells” that share the self-renewal feature of normal stem cells has changed the perspective with regard to new approaches for treating the disease. In recent years, biomedical research has revealed extraordinary diversity in the molecular basis of cancers, confusing attempts to find common underlying bases for therapeutic purposes. However, all clinically significant cancers share at least one common characteristic: excessive proliferation of affected cells, resulting in two main therapeutic approaches for combating cancerous cells. Differentiation therapy attempts to induce differentiation in cancer cells, as highly differentiated cells rarely divide. Alternatively, destruction therapy attempts to thwart malignant proliferation, since rapidly proliferating cells have poorly differentiated phenotypes. Both approaches have resulted in limited successes for certain cases, but neither approach completely cures cancer, targeting downstream cancerous cells, rather than the source.
Stem cells divide to produce two daughter cells: one exact copy, for continuous self-renewal and a second ”˜progenitor’ cell, which differentiates into mature cells that give rise to all the cell lineages in corresponding tissues. Stem cells have greater opportunity to accumulate genetic mutations, due to the combined ability for continuous self-renewal and the longer life span as compared with their cellular progeny. Any of the numerous signaling pathways that stem cells use to control normal self- renewal can be deregulated to produce cancer stem cells. The stem cell model of cancer suggests that accumulation of mutations in stem cells – or their early progenitor cells can result in the deregulation of self-renewal, leading to extensive proliferation abilities of the “cancer stem cells” and subsequent tumorigenesis.
The cancer stem cell model was first demonstrated in 1994 in John Dick’s lab, where scientists effectively induced tumorigenesis in severe combined immunodeficient (SCID) mice via the use of rare, leukemia-initiating stem cells purified from patients suffering from acute myelogenous leukemia (AML). Almost a decade later, Michael Clarke’s lab demonstrated the presence of breast cancer stem cells while Peter Dirk’s lab demonstrated the equivalent in brain cancer.
These cancer stem cells are rare (about 1 in 250,000 tumor cells), but are the only cells with the capability to produce a new tumor. The remaining majorities of cancer cells within established tumor are unable to maintain the tumor and are not capable of tumorigenesis. This scarcity of tumorigenic cancer stem cells with metastatic ability has important implications for cancer therapeutics, as these cells are insensitive to traditional therapeutics and are able to regrow tumors, even after the bulk of non-tumorigenic cancerous cells are removed. This provides an explanation for regrowth of tumor mass after removal of the bulk of the tumor and the lack of cure for certain types of cancers.
The cancer stem cell model has thus changed the perspective of cancer research and allows novel therapeutic strategies to advance. Clearly, the solution to effective therapies is to target the rare cells from whence the cancer originates, rather than all the cells of the tumor, in an effort to eliminate the disease itself and prevent these cancer stem cells from repopulating the tumor once the bulk is killed off. As cancer research advances, identifying and eliminating these cancer stem cells will become the basis for effective therapy, targeting the underlying basis of the disease and resulting in a possible cure for cancer.
And since all cancers spread (metastasize) via inflammatory processes, the optional preventive agent is a safe and effective anti-inflammatory agent. SOUL is made from 3 potent anti-inflammatory seeds.
To further understand the importance of addressing inflammation, see this critically important link